BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation.
Ontology highlight
ABSTRACT: The Raf murine sarcoma viral oncogene homolog B (BRAF) mutation is detected in 8-12% of metastatic colorectal cancers (mCRCs) and is strongly correlated with poor prognosis. The recent success of the BEACON CRC study and the development of targeted therapy have led to the determination of BRAF-mutated mCRCs as an independent category. For nearly two decades, a growing body of evidence has established the significance of the BRAF mutation in the development of CRC. Herein, we overview both basic and clinical data relevant to BRAF-mutated CRC, mainly focusing on the development of treatment strategies. This review is organized into eight sections, including clinicopathological features, molecular features, prognosis, the predictive value of anti-epidermal growth factor receptor (EGFR) therap
SUBMITTER: Nakayama I
PROVIDER: S-EPMC7694028 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA